NatPharm Confirms Drug Supply Stability — HIV, TB and Malaria Stocks to Last Through Year-End
The national pharmaceutical company, NatPharm, has assured the public that stocks of essential HIV, tuberculosis (TB), and malaria medicines are sufficient to last through the end of 2025.
This announcement comes as the country continues to strengthen its health supply chain and prepare for the upcoming year.
NatPharm Managing Director Newman Madzikwa confirmed that the supply of HIV medicines is currently stable, with support from the National AIDS Council and the Ministry of Health.
“We currently have sufficient medicines in the area of HIV. We have various supplies with the support that came from the National AIDS Council and the Ministry of Health. So we have products that can take us up to the end of the year,” he stated.
He indicated that procurement for the first half of 2026 will begin soon to ensure continuity.
“We are anticipating that the procurement for the first half of the year for 2026 will begin as soon as possible,” he said.
Madzikwa pointed out that there are no major concerns regarding HIV, TB, and malaria commodities.
“So we will be having no challenges with HIV commodities, as well as TB and malaria,” he noted.
However, he acknowledged minor challenges with other supplies.
“While we are having some challenges with other commodities for those high-impact interventions in the area of HIV, TB and malaria, we are still fairly okay,” he added.
According to ZBC, NatPharm is also ramping up its cholera preparedness plan ahead of the rainy season, which typically sees a rise in waterborne diseases.
“We are bringing in products to address potential outbreaks, including Aquatabs and normal saline.
“These supplies will be received shortly and distributed to provinces as part of our readiness strategy,” Madzikwa explained.
Looking ahead, NatPharm is working to operationalize memoranda of understanding signed with several international and regional pharmaceutical firms.
These agreements are expected to pave the way for local drug manufacturing, positioning the country to become a self-reliant producer of key medicines within the next decade.
